CNS Organoid Supply and Maintenance

The contract seeks the supply and ongoing maintenance of human CNS-3D brain organoids designated as 28Bio, which are engineered to express 5-HT5A serotonin receptors and demonstrate spontaneous calcium ion burst activity, making them suitable for advanced neuropharmacological studies. These organoids must consistently replicate key functional characteristics of human brain tissue, particularly in synaptic signaling and neuronal network dynamics, to support drug screening and neurological disease modeling. The provider is responsible for ensuring the organoids are viable, properly characterized, and delivered in a condition that preserves their physiological relevance throughout the supply cycle. Maintenance protocols must include standardized culture conditions, regular quality assurance testing, and documentation of functional stability, including confirmed expression of the 5-HT5A receptor and reproducible Ca²⁺ burst patterns across all batches. The work is classified as a subcontract under NAICS code 325414, indicating it falls within the biological product manufacturing sector, and is issued by the FDA Office of Acquisition and Grant Services under the Department of Health and Human Services. Responses are due by May 4, 2026, with no set-aside provisions specified; performance location and point of contact details are not provided, but all deliverables must meet the technical and operational requirements necessary for high-precision neuropharmacological research applications.